Monitoring B Cell Responses in Melanoma Patients
Author Information
Author(s): Gilbert Amy E., Karagiannis Panagiotis, Dodev Tihomir, Koers Alexander, Lacy Katie, Josephs Debra H., Takhar Pooja, Geh Jenny L. C., Healy Ciaran, Harries Mark, Acland Katharine M., Rudman Sarah M., Beavil Rebecca L., Blower Philip J., Beavil Andrew J., Gould Hannah J., Spicer James, Nestle Frank O., Karagiannis Sophia N.
Primary Institution: King’s College London
Hypothesis
The study investigates the role of mature B cells and their antibody responses in melanoma patients.
Conclusion
The study found that melanoma patients have a significant presence of tumor-reactive antibodies, which decrease with disease progression.
Supporting Evidence
- 28% of melanoma patient-derived B cell cultures produced antibodies that recognized melanoma cells.
- 2% of cultures from healthy controls produced similar antibodies.
- Antibody responses decreased with advancing disease stage.
Takeaway
This study shows that people with melanoma have special cells in their blood that can make antibodies to fight the cancer, but these cells are less effective as the cancer gets worse.
Methodology
The study used a cell-based ELISA to evaluate IgG antibody responses from B cells of melanoma patients and healthy volunteers.
Limitations
The study primarily focused on antibodies against metastatic melanoma cells, which may not account for responses to primary disease antigens.
Participant Demographics
The patient cohort was almost exclusively Caucasian.
Statistical Information
P-Value
p<0.0001
Confidence Interval
95% CI 2.4 to 2.6
Statistical Significance
p<0.0001
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website